CONTX ContextVision AB (publ)
ContextVision AB (publ), a software company, provides image analysis and imaging for medical systems in South Korea, China, Japan, the United States, and internationally. The company offers image quality solutions for ultrasound, as well as its Rivent platform comprising Rivent, a 2D image enhancement; Rivent Plus, a premium 2D image enhancement product; Rivent 3D, a solution for improving image quality of 3D ultrasound; and Rivent Mobile, a 2D image enhancement for handheld devices for diagnostics in various fields, including radiology, cardiology, women's health, veterinary medicine, and point of-care applications. It also provides Altumira platform, which features scatter correction and improves radiography by enabling radiation dose reduction while enhancing image quality, such as Altumira for static applications; and Altumira Plus for dynamic applications. In addition, the company offers image quality solutions for MRI including GOPView MRI2Plus for the requirements of each application, sequence type, and protocol; and implementation projects, software updates, and upgrades and product support services. It has a strategic clinical development partnership with the University of Washington to identify a multiparametric biomarker for the screening and staging of the liver disease MASLD; and research partnership with AMRA Medical. ContextVision AB (publ) was incorporated in 1989 and is headquartered in Stockholm, Sweden.…
Industry Peers
Health Information ServicesKey Statistics
About ContextVision (OSL: CONTX)
›
ContextVision (OSL: CONTX) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 42 employees.
The shares were at 4.000 NOK on 19 November 2026, down 10.1% over 52 weeks. Its 52-week range is 2.700 NOK to 5.780 NOK: the price is 30.8% below the high and 48.1% above the low.
At a market capitalisation of 292.76M NOK, it trades at 15.4 times trailing earnings and 21.1 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 63% for CONTX.
ContextVision reports return on equity of 0.8%, an operating margin of 0.0% and revenue up 11.5% year over year.
Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 18 February 2027.